|
[1]XU J, KISSELEVA T.Bone marrow-derived fibrocytes contribute to liver fibrosis[J].Exp Biol Med (Maywood) , 2015, 240 (6) :691-700.
|
|
[2]ELPEK GO.Cellular and molecular mechanisms in the pathogenesis of liver fibrosis:an update[J].World J Gastroentero, 2014, 20 (23) :7260-7276.
|
|
[3]SEKI E, BRENNER DA.Recent advancement of molecular mechanisms of liver fibrosis[J].J Hepato-Bil-Pan Sci, 2015, 22 (7) :512-518.
|
|
[4]DUFFIELD JS, FORBES SJ, CONSTANDINOU CM, et al.Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair[J].J Clin Invest, 2005, 115 (1) :56-65.
|
|
[5]LI H, YOU H, FAN X, et al.Hepatic macrophages in liver fibrosis:pathogenesis and potential therapeutic targets[J].BMJ Open Gastroenterology, 2016, 3 (1) :e000079.
|
|
[6] LEE YA, WALLACE MC, FRIEDMAN SL.Pathobiology of liver fibrosis:a translational success story[J].Gut, 2015, 64 (5) :830-841.
|
|
[7]MARX V.Autophagy:eat thyself, sustain thyself[J].Nat Methods, 2015, 12 (12) :1121-1125.
|
|
[8]MALLAT A, LODDER J, TEIXEIRA-CLERC F, et al.Autophagy:a multifaceted partner in liver fibrosis[J].Biomed Res Int, 2014, 2014 (8) :1-7.
|
|
[9]ROY S, BENZ F, LUEDDE T, et al.The role of miRNAs in the regulation of inflammatory processes during hepatofibrogenesis[J].Hepatobiliary Surg Nutr, 2015, 4 (1) :24-33.
|
|
[10]RODERBURG C, MOLLNOW T, BONGAERTS B, et al.MicroRNA profiling in human serum reveals compartment-specific roles of miR-571 and miR-652 in liver cirrhosis[J].PLoS One, 2012, 7 (3) :e32999.
|
|
[11]SZABO G, BALA S.MicroRNAs in liver disease[J].Nat Rev Gastro Hepat, 2013, 10 (9) :542-552.
|
|
[12]ANADOL E, SCHIERWAGEN R, ELFIMOVA N, et al.Circulating microRNAs as a marker for liver injury in human immunodeficiency virus patients[J].Hepatology, 2015, 61 (1) :46-55.
|
|
[13]XU S, WANG Y, TAI DC, et al.q Fibrosis:a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients[J].J Hepatol, 2014, 61 (2) :260-269.
|
|
[14]SUN Y, ZHOU J, WANG L, et al.New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment[J].Hepatology, 2016.[Epub ahead of print]
|
|
[15]BARANOVA A, LAL P, BIRERDINC A, et al.Non-invasive markers for hepatic fibrosis[J].BMC Gastroenterol, 2011, 11 (1) :91.
|
|
[16]JIA J, HOU J, DING H, et al.Transient elastography compared to serum markers to predict liver fibrosis in a cohort of Chinese patients with chronic hepatitis B[J].J Gastroen Hepatol, 2015, 30 (4) :756-762.
|
|
[17]CHENG J, HOU J, DING H, et al.Validation of ten noninvasive diagnostic models for prediction of liver fibrosis in patients with chronic hepatitis B[J].PLoS One, 2015, 10 (12) :e144425.
|
|
[18]ELLIS EL, MANN DA.Clinical evidence for the regression of liver fibrosis[J].J Hepatol, 2012, 56 (5) :1171-1180.
|
|
[19]D'AMBROSIO R, AGHEMO A, RUMI MG, et al.A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis[J].Hepatology, 2012, 56 (2) :532-543.
|
|
[20]MARCELLIN P, GANE E, BUTI M, et al.Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B:a 5-year open-label follow-up study[J].Lancet, 2013, 381 (9865) :468-475.
|
|
[21]NEVENS F, ANDREONE P, MAZZELLA G, et al.A Placebocontrolled trial of obeticholic acid in primary biliary cholangitis[J].N Engl J Med, 2016, 375 (7) :631-643.
|
|
[22]NEUSCHWANDER-TETRI BA, LOOMBA R, SANYAL AJ, et al.Farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, non-alcoholic steatohepatitis (FLINT) :a multicentre, randomised, placebo-controlled trial[J].The Lancet, 2015, 385 (9972) :956-965.
|
|
[23]FAGONE P, MANGANO K, PESCE A, et al.Emerging therapeutic targets for the treatment of hepatic fibrosis[J].Drug Discov Today, 2016, 21 (2) :369-375.
|
|
[24]PALUMBO-ZERR K, ZERR P, DISTLER A, et al.Orphan nuclear receptor NR4A1 regulates transforming growth factor-βsignaling and fibrosis[J].Nat Med, 2015, 21 (2) :150-158.
|
|
[25]WANG Q, USINGER W, NICHOLS B, et al.Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease[J].Fibrogenesis Tissue Repair, 2011, 4 (1) :4.
|
|
[26]CHAKRABORTY JB, MANN DA.NF-κB signalling:embracing complexity to achieve translation[J].J Hepatol, 2010, 52 (2) :285-291.
|
|
[27]WU L, MAO C, MING X.Modulation of Bcl-x alternative splicing induces apoptosis of human hepatic stellate cells[J].Biomed Res Int, 2016, 2016 (2) :1-7.
|
|
[28]GAO B, RADAEVA S, PARK O.Liver natural killer and natural killer T cells:immunobiology and emerging roles in liver diseases[J].J Leukoc Biol, 2009, 86 (3) :513-528.
|
|
[29]CONG M, LIU T, WANG P, et al.Antifibrotic effects of a recombinant adeno-associated virus carrying small interfering RNA targeting TIMP-1 in rat liver fibrosis[J].Am J Pathol, 2013, 182 (5) :1607-1616.
|
|
[30]BARRY-HAMILTON V, SPANGLER R, MARSHALL D, et al.Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment[J].Nat Med, 2010, 16 (9) :1009-1017.
|
|
[31]MEISSNER EG, MCLAUGHLIN M, MATTHEWS L, et al.Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults:results of a 6-month open-label safety trial[J].Liver Int, 2016, 36 (12) :1783-1792.
|
|
[32]EOM YW, SHIM KY, BAIK SK.Mesenchymal stem cell therapy for liver fibrosis[J].Korean J Intern Med, 2015, 30 (5) :580-589.
|
|
[33]SHI M, ZHANG Z, XU R, et al.Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients[J].Stem Cells Transl Med, 2012, 1 (10) :725-731.
|
|
[34]WANG P, CONG M, LIU TH, et al.Primary isolated hepatic oval cells maintain progenitor cell phenotypes after two-year prolonged cultivation[J].J Hepatol, 2010, 53 (5) :863-871.
|
PDF下载 ( 1541 KB)
本文二维码
下载:
